The role of risk scores for prediction of adverse events in patients undergoing PCI.

Dual antiplatelet therapy (DAPT) is the cornerstone of medical therapy in patients undergoing percutaneous coronary intervention. DAPT decreases the risk for ischemic events, including stent related complication as e.g. stent thrombosis, but increases the risk of bleeding. Current guidelines endorse DAPT after PCI for 6 months in stable patients, and 12 months in patients presenting with acute coronary syndrome (ACS), but with further options to adapt DAPT duration according to the patient's risk profile for ischemic or bleeding complications [1].